PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models
Hien Tran Zhao, … , Eric E. Swayze, Holly B. Kordasiewicz
Hien Tran Zhao, … , Eric E. Swayze, Holly B. Kordasiewicz
Published December 4, 2017
Citation Information: J Clin Invest. 2018;128(1):359-368. https://doi.org/10.1172/JCI96499.
View: Text | PDF
Research Article Neuroscience Therapeutics

PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models

Abstract

Charcot-Marie-Tooth disease type 1A (CMT1A) is caused by duplication of peripheral myelin protein 22 (PMP22) and is the most common hereditary peripheral neuropathy. CMT1A is characterized by demyelination and axonal loss, which underlie slowed motor nerve conduction velocity (MNCV) and reduced compound muscle action potentials (CMAP) in patients. There is currently no known treatment for this disease. Here, we show that antisense oligonucleotides (ASOs) effectively suppress PMP22 mRNA in affected nerves in 2 murine CMT1A models. Notably, initiation of ASO treatment after disease onset restored myelination, MNCV, and CMAP almost to levels seen in WT animals. In addition to disease-associated gene expression networks that were restored with ASO treatment, we also identified potential disease biomarkers through transcriptomic profiling. Furthermore, we demonstrated that reduction of PMP22 mRNA in skin biopsies from ASO-treated rats is a suitable biomarker for evaluating target engagement in response to ASO therapy. These results support the use of ASOs as a potential treatment for CMT1A and elucidate potential disease and target engagement biomarkers for use in future clinical trials.

Authors

Hien Tran Zhao, Sagar Damle, Karli Ikeda-Lee, Steven Kuntz, Jian Li, Apoorva Mohan, Aneeza Kim, Gene Hung, Mark A. Scheideler, Steven S. Scherer, John Svaren, Eric E. Swayze, Holly B. Kordasiewicz

×

Figure 3

Myelination and electrophysiological improvement after ASO treatment in a rat model of CMT1A.

Options: View larger image (or click on image) Download as PowerPoint
Myelination and electrophysiological improvement after ASO treatment in ...
CMT1A rats were treated weekly for 12 weeks with PBS, control ASO (12.5 mg/kg), or ASO6 (12.5 mg/kg). n = 10 per group. WT littermates treated with PBS were included as control. n = 10 per group. (A) Rat Pmp22 mRNA in various nerves of control and ASO6-treated rats. ASO6-treated group was compared with control group in each nerve using Student’s t test. *P < 0.05; ***P < 0.001. (B) Pou3f1 mRNA in various nerves of control and ASO6-treated rats. PMP22 ASO–treated group was compared with control group in each nerve using Student’s t test. *P < 0.05; ***P < 0.001. (C and D) MNCV and CMAP were measured at 12 weeks following treatment. (E) Representative histological image of cross-sectioned femoral motor nerves of CMT1A rats treated with control or ASO6. Arrows and arrowheads indicate unmyelinated and myelinated axon of greater than 1 micron in diameter, respectively. Scale bar: 5 μm. (F) Quantification of percentage of myelinated and percentage of unmyelinated axons. ASO6-treated group was compared with control group using Student’s t test. **P < 0.01. (G) qRT-PCR confirmation of mRNA expression of lipid biosynthetic (Sc5dl and Ugt8a), myelin inhibitor (Id2), and translational repressor (Bzw2) genes in the sciatic nerve of control vs. ASO6-treated rats. ASO6-treated group was compared with control group in each nerve using Student’s t test. ***P < 0.001. (H) Rat Pmp22 mRNA in footpad following control or ASO6 treatment. ASO6-treated group was compared with control group using Student’s t test. *P < 0.05.